article thumbnail

Clinical development and proof of principle testing of new regenerative vascular endothelial growth factor-D therapy for refractory angina: rationale and design of the phase 2 ReGenHeart trial

Open Heart

Background Despite tremendous therapeutic advancements, a significant proportion of coronary artery disease patients suffer from refractory angina pectoris, that is, quality-of-life-compromising angina that is non-manageable with established pharmacological and interventional treatment options.

Angina 52
article thumbnail

Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial

Frontiers in Cardiovascular Medicine

Furthermore, we utilized mass spectrometry analysis, network pharmacology, and lipidomics to predict the potential mechanisms of FFDS in the treatment of SCHD.ResultsFollowing treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P=0.013) and a reduction in the frequency of angina episodes (P=0.021).

article thumbnail

Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars)

Heart BMJ

The 91 villages underwent random allocation into two arms: the control arm, encompassing 45 clusters, was subjected to non-pharmacological intervention (educational training on healthy lifestyle), whereas the intervention arm, comprising 46 clusters, received the non-pharmacological interventions in conjunction with a once-daily polypill tablet.

article thumbnail

Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain

Frontiers in Cardiovascular Medicine

Patients with a new or recurrent episode of ASCVD (angina, acute myocardial infarction, transient ischemic attack, stroke, or peripheral arterial disease) between 1-Jan-2017 and 31-Dec-2018 were included. The costs derived from pharmacological treatments were obtained from the NHS pricing nomenclator database ( [link] ).

article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24

article thumbnail

The efficacy of traditional Chinese herbal medicine across multiple cardiovascular diseases: an umbrella review of systematic reviews of randomized controlled trials

Journal of Cardiovascular Pharmacology

The favorable efficacy of CHM was primarily presented on five main conditions, coronary artery disease, hypertension, heart failure, restenosis, and angina pectoris. The favorable efficacy of CHM was primarily presented on five main conditions, coronary artery disease, hypertension, heart failure, restenosis, and angina pectoris.

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

mg experienced a 23% lower incidence of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization in a time-to-event analysis. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.